Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer - Wikidata - wikimedia - TriplyDB

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

http://www.wikidata.org/entity/Q28275904

about

Polyunsaturated fatty acid metabolism in prostate cancer Heparan sulphate synthetic and editing enzymes in ovarian cancer Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy Insidious changes in stromal matrix fuel cancer progression Heparan sulfate signaling in cancer Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.The Extracellular Matrix in Epithelial Ovarian Cancer - A Piece of a Puzzle.The role of the tumor stroma in ovarian cancer.Endogenous synthesis of n-3 polyunsaturated fatty acids in Fat-1 mice is associated with increased mammary gland and liver syndecan-1.The motile breast cancer phenotype roles of proteoglycans/glycosaminoglycans.Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2.Syndecan-1 (CD 138) surface expression marks cell type and differentiation in ameloblastoma, keratocystic odontogenic tumor, and dentigerous cyst.Decidualization and syndecan-1 knock down sensitize endometrial stromal cells to apoptosis induced by embryonic stimuli Prognostic significance of syndecan-1 expression in cervical cancers.Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.Toward an integrative analysis of the tumor microenvironment in ovarian epithelial carcinoma.ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis Superficial spreading squamous cell carcinoma of the uterine cervix involving the endometrium: Report of two cases with emphasis on the likely molecular mechanism Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.Proteoglycans in cancer biology, tumour microenvironment and angiogenesis.Differential expression of syndecans and glypicans in chronically inflamed synovium.Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma.Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions.Proteoglycans in prostate cancer.Targeting syndecans: a promising strategy for the treatment of cancer.Syndecan-1 knockdown in endometrial epithelial cells alters their apoptotic protein profile and enhances the inducibility of apoptosis.Shed proteoglycans in tumor stroma.Sdc1 negatively modulates carcinoma cell motility and invasion.Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy.Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells.Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma.Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.Syndecan-1 regulates adipogenesis: new insights in dedifferentiated liposarcoma tumorigenesis.Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression

P2860

Q24629893-D3DB195F-9614-4FC6-91C9-80FE6C3A9748 Q24653774-4E82EC4C-1E51-4035-81A8-FE2B48DBFBBF Q26784262-BD462326-FB1C-4A6A-AE9D-E3BC257BFE89 Q26796247-7B80ACF3-8540-4BD6-A26C-387519BBCFCF Q26800258-6C8FAB69-6560-4229-ABE5-4738C3C282C8 Q26851261-825066EA-A6B7-4833-8348-2631C969D567 Q28657828-354C4FA2-C976-4279-8D4B-2D02C6673BB4 Q30366990-AEA59608-A798-4EB1-9EDA-B1000CBE503F Q33361929-4625D2D8-7203-495D-94A8-B9DC475E7546 Q33633856-4653398C-4256-48D0-8865-DDCD7A491F6C Q33927026-15021936-5825-440A-BB40-D9A7A9317D1D Q34031745-72FD5ADB-F2DE-4282-8CC3-391DA37A6598 Q34177237-550FC949-F820-42F8-A8C2-8415786178C4 Q34268238-216BA197-BDE0-4D85-A08A-6982ABCE83BE Q34321430-E0E28A32-2F2E-4D16-99B4-86633A755E01 Q34322029-A627D1E3-DF43-430F-8419-71B6C6FCDF90 Q35243043-FF30C706-D957-4C00-8AFF-30889B234FF1 Q35285294-E5AA0E1C-300D-4907-AD3D-67C07F66F0A9 Q35768137-2285DECE-9611-4D34-8080-2CED67E423DD Q36101228-57456811-1E4F-49A0-80F3-0C1E3724B417 Q36235795-788D39AF-173E-4002-8A3D-1155AB2E2974 Q36387694-331BB7D0-754B-45D4-AF93-2BE1B2493220 Q36475802-453AC22A-7906-49CC-926B-7F4CBD0BA890 Q36769318-A4F79B09-D479-40A5-9AB4-90E03A4DD406 Q36787608-8989F8F4-88E0-42E2-830C-192FEE231720 Q36927550-F1B4B0BA-14F9-436D-8FAA-57C6765A1B31 Q37525296-CA9C408C-ED2B-4582-9F6E-3C5549DD21E0 Q37636855-D7FEACA2-9CD1-4588-81C9-BCA8144F49E1 Q37986399-2063F965-A030-4482-BF24-37C3F53A41B0 Q38082795-E61BB560-DDFF-40C4-945D-04DE9377B30D Q38309339-2ED4E15F-DF1D-438C-B1C1-484F94B36F3E Q38882752-72D05596-9FCB-4F69-8EFB-62F4B23D8804 Q39494666-8C771DED-24C5-434E-BBA5-04791B5FE0BC Q40063020-BB72F565-EC1B-4253-BC1C-91EED4146A16 Q40297851-BF495ADE-4DA2-4B5A-89B1-B954B0D1CBF3 Q45351456-A9650ABA-9003-4E5C-B4DD-5F1C48F43197 Q48923743-1E94C9C1-5977-41D2-B4D9-5BEAA7B48AA1 Q51040058-2ED9DB3A-C557-49CE-A9BF-1214311BC92C Q52714362-E14B695D-EC39-468A-96BE-8C19C72F3298 Q58705289-FCAAD68F-4C6B-4A3D-84FC-FE32F1DE7FC5

P2860

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

http://www.wikidata.org/entity/Q28275904

description

2004 nî lūn-bûn

@nan

2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

@ast

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

@en

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

@nl

type

label

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

@ast

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

@en

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

@nl

prefLabel

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

@ast

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

@en

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

@nl

P1433

Q28275904-C09F4E32-C652-401A-A1BA-E1B7ABD9F3CE

P1476

Q28275904-DF0C1EEB-DCC0-44DF-8DE5-CECCFB4D9806

P2093

Q28275904-2E670169-677D-4264-9337-19A56258E73C

Q28275904-42FB3048-C2AA-4768-94BF-A179BC615BEC

Q28275904-456E81FA-1922-4FAF-AD62-3EE56649D587

Q28275904-7B2FA1DD-99BF-4430-BC91-B48CAB8F96A8

Q28275904-7FC52F05-7059-471A-B25C-D67E27357DC3

Q28275904-812F968C-7D9C-4B70-9A81-65AB56EF4742

Q28275904-8EAFF9B1-1ABF-41DF-8790-1295AE7AC31E

Q28275904-B3741822-141D-4AC8-A334-FE8A914C048F

Q28275904-C18CF2ED-090E-429C-98B5-DC7B59BB5486

Q28275904-E1783138-8687-4934-B0C8-F26648D43F47

P304

Q28275904-289A9DF7-E632-4878-A4C0-3F28DA811434

P31

Q28275904-9CA14B7A-D9DA-4435-8B5D-49DD9B8270BE

P3181

Q28275904-2421B6B2-FE13-43B2-AB31-3F5896A1BD2D

P356

Q28275904-F7FDC6C3-8429-4848-9DDC-47B5BACC20D7

P407

Q28275904-0EC8E432-CF48-457D-B0E8-398455C25FF1

P433

Q28275904-ECBEA408-50BF-4B1B-8E29-000EDF7BCEE8

P478

Q28275904-55922477-9FA3-47DF-A15B-692B02CAC204

P577

Q28275904-F47CB3B6-D669-47D0-A8EB-30C955E65A92

P698

Q28275904-9EC386DC-AB81-4302-87D6-46F8B7D477D4

P921

Q28275904-2D4F0294-C85D-4FBD-A3B7-F1BFDCBA2EA0

P3181

P356

1078-0432.CCR-03-0103

P1433

Clinical Cancer Research

P1476

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer

@en

P2093

Alan T McGown

http://www.w3.org/2001/XMLSchema#string

E June Davies

http://www.w3.org/2001/XMLSchema#string

Fiona H Blackhall

http://www.w3.org/2001/XMLSchema#string

Gordon C Jayson

http://www.w3.org/2001/XMLSchema#string

Guido David

http://www.w3.org/2001/XMLSchema#string

John T Gallagher

http://www.w3.org/2001/XMLSchema#string

Jonathan H Shanks

http://www.w3.org/2001/XMLSchema#string

Pierre Martin-Hirsch

http://www.w3.org/2001/XMLSchema#string

Ric Swindell

http://www.w3.org/2001/XMLSchema#string

Richard J Slade

http://www.w3.org/2001/XMLSchema#string

P304

5178-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2463648

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-03-0103

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15297422

http://www.w3.org/2001/XMLSchema#string

P921